Edition:
United Kingdom

People: AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

13.96USD
16 Sep 2019
Change (% chg)

$-0.39 (-2.72%)
Prev Close
$14.35
Open
$14.31
Day's High
$14.50
Day's Low
$13.78
Volume
241,904
Avg. Vol
171,208
52-wk High
$39.27
52-wk Low
$11.90

Mariani, Peter 

Mr. Peter J. Mariani is the Chief Financial Officer of the AxoGen, Inc. Prior to joining Axogen, he served as Chief Financial Officer of Lensar, Inc, a privately held laser refractive cataract surgery company, from July 2014 through January 2016, which was sold in December 2015. From June 2011 to June 2014 Mr. Mariani served as Chief Financial Officer of Hansen Medical, a publicly traded medical device company developing robotic solutions for intravascular procedures. From 2007 through 2010 Mr. Mariani served as Chief Financial Officer for two privately held companies: Harlan Laboratories (2007 – 2009); and BMW Constructors (2009 – 2010). From 1994 through 2006 Mr. Mariani served in various senior financial roles with Guidant Corporation, a publicly traded leader in the development and sale of medical devices for the treatment of cardiovascular disease. Mr. Mariani began his career with Guidant Corporation as Director of Corporate Financial Reporting where he supported the initial public offering of Guidant Corporation and ultimately served as Vice President, Controller and Chief Accounting Officer. Mr. Mariani’s experience at Guidant Corporation included two years as Director of Financial Reporting, Guidant Vascular Intervention in Santa Clara, California, and four years in Tokyo, Japan, mostly as Vice President Finance and Administration where he helped to facilitate the conversion and scale of the Japan business from a distributor network to a direct sales and marketing organization. Following the 2006 sale of Guidant Corporation to Boston Scientific Corporation, Mr. Mariani co-led the initial integration of the two companies. From 1987 to 1994, Mr. Mariani worked with Ernst and Young,

Basic Compensation

Total Annual Compensation, USD 483,840
Restricted Stock Award, USD 558,900
Long-Term Incentive Plans, USD --
All Other, USD 613,411
Fiscal Year Total, USD 1,656,150

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --